Layal Chaker1, Marten E van den Berg1, Maartje N Niemeijer1, Oscar H Franco1, Abbas Dehghan1, Albert Hofman1, Peter R Rijnbeek1, Jaap W Deckers1, Mark Eijgelsheim1, Bruno H C Stricker2, Robin P Peeters1. 1. From Rotterdam Thyroid Center (L.C., R.P.P.), Department of Internal Medicine (L.C., B.H.C.S., R.P.P.), and Department of Epidemiology (L.C., M.E.v.d.B., M.N.N., O.H.F., A.D., A.H., M.E., B.H.C.S., R.P.P.), Erasmus University Medical Center; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A.H.); Departments of Medical Informatics (P.R.R.) and Cardiology (J.W.D.), Erasmus University Medical Center, Rotterdam, The Netherlands; and Inspectorate of Health Care, Utrecht, The Netherlands (B.H.C.S.). 2. From Rotterdam Thyroid Center (L.C., R.P.P.), Department of Internal Medicine (L.C., B.H.C.S., R.P.P.), and Department of Epidemiology (L.C., M.E.v.d.B., M.N.N., O.H.F., A.D., A.H., M.E., B.H.C.S., R.P.P.), Erasmus University Medical Center; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A.H.); Departments of Medical Informatics (P.R.R.) and Cardiology (J.W.D.), Erasmus University Medical Center, Rotterdam, The Netherlands; and Inspectorate of Health Care, Utrecht, The Netherlands (B.H.C.S.). b.stricker@erasmusmc.nl.
Abstract
BACKGROUND: The association between thyroid function and cardiovascular disease is well established, but no study to date has assessed whether it is a risk factor for sudden cardiac death (SCD). Therefore, we studied the association of thyroid function with SCD in a prospective population-based cohort. METHODS: Participants from the Rotterdam Study ≥45 years with thyroid-stimulating hormone or free thyroxine (FT4) measurements and clinical follow-up were eligible. We assessed the association of thyroid-stimulating hormone and FT4 with the risk of SCD by using an age- and sex-adjusted Cox proportional-hazards model, in all participants and also after restricting the analysis to euthyroid participants (defined by thyroid-stimulating hormone 0.4-4.0 mIU/L). Additional adjustment included cardiovascular risk factors, notably hypertension, serum cholesterol, and smoking. We stratified by age and sex and performed sensitivity analyses by excluding participants with abnormal FT4 values (reference range of 0.85-1.95 ng/dL) and including only witnessed SCDs as outcome. Absolute risks were calculated in a competing risk model by taking death by other causes into account. RESULTS: We included 10 318 participants with 261 incident SCDs (median follow-up, 9.1 years). Higher levels of FT4 were associated with an increased SCD risk, even in the normal range of thyroid function (hazard ratio, 2.28 per 1 ng/dL FT4; 95% confidence interval, 1.31-3.97). Stratification by age or sex and sensitivity analyses did not change the risk estimates substantially. The absolute 10-year risk of SCD increased in euthyroid participants from 1% to 4% with increasing FT4 levels. CONCLUSIONS: Higher FT4 levels are associated with an increased risk of SCD, even in euthyroid participants.
BACKGROUND: The association between thyroid function and cardiovascular disease is well established, but no study to date has assessed whether it is a risk factor for sudden cardiac death (SCD). Therefore, we studied the association of thyroid function with SCD in a prospective population-based cohort. METHODS:Participants from the Rotterdam Study ≥45 years with thyroid-stimulating hormone or free thyroxine (FT4) measurements and clinical follow-up were eligible. We assessed the association of thyroid-stimulating hormone and FT4 with the risk of SCD by using an age- and sex-adjusted Cox proportional-hazards model, in all participants and also after restricting the analysis to euthyroid participants (defined by thyroid-stimulating hormone 0.4-4.0 mIU/L). Additional adjustment included cardiovascular risk factors, notably hypertension, serum cholesterol, and smoking. We stratified by age and sex and performed sensitivity analyses by excluding participants with abnormal FT4 values (reference range of 0.85-1.95 ng/dL) and including only witnessed SCDs as outcome. Absolute risks were calculated in a competing risk model by taking death by other causes into account. RESULTS: We included 10 318 participants with 261 incident SCDs (median follow-up, 9.1 years). Higher levels of FT4 were associated with an increased SCD risk, even in the normal range of thyroid function (hazard ratio, 2.28 per 1 ng/dL FT4; 95% confidence interval, 1.31-3.97). Stratification by age or sex and sensitivity analyses did not change the risk estimates substantially. The absolute 10-year risk of SCD increased in euthyroid participants from 1% to 4% with increasing FT4 levels. CONCLUSIONS: Higher FT4 levels are associated with an increased risk of SCD, even in euthyroid participants.
Authors: Vincenzo Di Donna; Rosa Maria Paragliola; Chiara de Waure; Giampaolo Papi; Alfredo Pontecorvi; Salvatore Maria Corsello Journal: Endocrine Date: 2017-05-02 Impact factor: 3.633
Authors: M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman Journal: Eur J Epidemiol Date: 2017-10-24 Impact factor: 8.082
Authors: Christine Baumgartner; Bruno R da Costa; Tinh-Hai Collet; Martin Feller; Carmen Floriani; Douglas C Bauer; Anne R Cappola; Susan R Heckbert; Graziano Ceresini; Jacobijn Gussekloo; Wendy P J den Elzen; Robin P Peeters; Robert Luben; Henry Völzke; Marcus Dörr; John P Walsh; Alexandra Bremner; Massimo Iacoviello; Peter Macfarlane; Jan Heeringa; David J Stott; Rudi G J Westendorp; Kay-Tee Khaw; Jared W Magnani; Drahomir Aujesky; Nicolas Rodondi Journal: Circulation Date: 2017-10-23 Impact factor: 29.690
Authors: Arjola Bano; Klodian Dhana; Layal Chaker; Maryam Kavousi; M Arfan Ikram; Francesco U S Mattace-Raso; Robin P Peeters; Oscar H Franco Journal: JAMA Intern Med Date: 2017-11-01 Impact factor: 21.873
Authors: João Sérgio Neves; Ricardo Fontes-Carvalho; Marta Borges-Canha; Ana Rita Leite; Sandra Martins; Ana Oliveira; João Tiago Guimarães; Davide Carvalho; Adelino Leite-Moreira; Ana Azevedo Journal: Eur Thyroid J Date: 2020-07-08
Authors: Nicole Lafontaine; Purdey J Campbell; Juan E Castillo-Fernandez; Shelby Mullin; Ee Mun Lim; Phillip Kendrew; Michelle Lewer; Suzanne J Brown; Rae-Chi Huang; Phillip E Melton; Trevor A Mori; Lawrence J Beilin; Frank Dudbridge; Tim D Spector; Margaret J Wright; Nicholas G Martin; Allan F McRae; Vijay Panicker; Gu Zhu; John P Walsh; Jordana T Bell; Scott G Wilson Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958
Authors: Rudolf Hoermann; John E M Midgley; Rolf Larisch; Johannes W Dietrich Journal: Front Endocrinol (Lausanne) Date: 2016-11-07 Impact factor: 5.555
Authors: Daniel Bos; Arjola Bano; Albert Hofman; Tyler J VanderWeele; Maryam Kavousi; Oscar H Franco; Meike W Vernooij; Robin P Peeters; M Arfan Ikram; Layal Chaker Journal: Clin Epidemiol Date: 2018-03-01 Impact factor: 4.790